Agenus Expands Medical Affairs Infrastructure to Support Physician Requests for Botensilimab Plus Balstilimab Access

Agenus expands its Medical Affairs infrastructure to support increasing requests for authorized access to botensilimab plus balstilimab, an immunotherapy combination for advanced solid tumors. This expansion reflects growing interest from treating oncologists worldwide, who have exhausted standard-of-care treatment options. Patients have already been treated with BOT+BAL through regulatory-authorized paid named patient programs in multiple countries.